For the first time we will be including clinical trial data in our updated research report, Commercial Trends for Biomarker-Based IVD Tests, and here is an early look at some data describing how biomarkers are being used in drug development.
Biomarker Use by Trial Phase
For clinical trials registered in 2013, biomarkers are being used most often in phase 2 trials.
Biomarkers are listed in approximately 25% of all phase 2 clinical trials registered during 2013, more than double the average across all trial phases.
In all, approximately 12% of all clinical trials registered during 2013 include biomarkers in the Outcome Measures and/or the Inclusion Criteria.